Campbell, CA - Myra Vision, a pioneering medical device company focused on transforming the treatment of glaucoma, announced today the successful closure of its Series B funding round, raising an impressive $25 million. The round was led by The Capital Partnership, a renowned investment firm specializing in healthcare technologies, and Shifamed, a prominent venture capital firm known for its support of innovative medical advancements.

Glaucoma, a debilitating eye disease affecting millions worldwide, has long been a challenging condition to manage effectively. Myra Vision, founded by visionary entrepreneur Robert Chang, aims to revolutionize the field by introducing a groundbreaking treatment approach that offers personalized flow and precise intraocular pressure (IOP) control. Their innovative solution has the potential to transform the lives of patients suffering from moderate to severe glaucoma.

Robert Chang, the founder of Myra Vision, expressed his gratitude for the trust placed in the company by these esteemed investors. He stated, "We are thrilled to have The Capital Partnership and Shifamed as partners in our mission to provide a life-changing solution for patients with glaucoma. This funding will enable us to further advance the development and commercialization of our pioneering technology, bringing new hope to individuals battling this devastating eye disease."